An Open-Label Study of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors

INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.

Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.